4//SEC Filing
ANIDO ARMANDO 4
Accession 0001062993-23-001384
CIK 0001621443other
Filed
Jan 24, 7:00 PM ET
Accepted
Jan 25, 5:25 PM ET
Size
8.3 KB
Accession
0001062993-23-001384
Insider Transaction Report
Form 4
ANIDO ARMANDO
DirectorChairman & Chief Exec. Officer
Transactions
- Award
Common Stock
2023-01-24+250,000→ 826,235 total - Sale
Common Stock
2023-01-23$0.60/sh−35,453$21,194→ 576,235 total
Holdings
- 26,595(indirect: See footnote)
Common Stock
- 13,297(indirect: See footnote)
Common Stock
Footnotes (3)
- [F1]This transaction represents shares required to be sold by the Reporting Person to satisfy tax obligations and certain equity plan administrator fees in connection with the vesting of shares of restricted stock. This sale was mandated by the equity plan administrator and does not represent a discretionary trade by the Reporting Person.
- [F2]The restricted stock award will fully vest in two installments, subject to continued employment with the Company through the applicable vesting date: 1/3 of the restricted stock will vest on February 1, 2024; and 2/3 of the restricted stock will vest on February 1, 2025.
- [F3]TUA of Armando Anido and Nancy J. Anido Trusts are controlled by Armando Anido, who has voting and dispositive power with respect to shares held by the trusts.
Issuer
Zynerba Pharmaceuticals, Inc.
CIK 0001621443
Entity typeother
Related Parties
1- filerCIK 0001219866
Filing Metadata
- Form type
- 4
- Filed
- Jan 24, 7:00 PM ET
- Accepted
- Jan 25, 5:25 PM ET
- Size
- 8.3 KB